Incidence of Falls Is Common in Older Adults with Newly Diagnosed MM

Conference Correspondent  - TON - ASH 2015 - Multiple Myeloma, Conference Correspondent

Multiple myeloma (MM) is disproportionately prevalent in older adults. The prognosis for these patients is influenced by a number of factors, including comorbidities and dependence in daily activities. Here, falls are postulated as another factor that may be associated by poorer outcomes among older adults with MM. This study sought to determine the prevalence of falls in a cohort of older adults with newly diagnosed MM and examine associations between falls and functional status, comorbidities, and self-reported health.

National epidemiologic data and self-reported data from the Medicare Health Outcomes Survey were used to identify patients with a diagnosis of MM who experienced at least 1 fall during the study period. Associations between falls and patient-reported data on function, comorbidities, and self-rated health were examined using standard statistical methods for this type of analysis. Researchers identified 1327 unique patients, of whom 376 completed their baseline Medicare Health Outcomes Survey within 1 year of diagnosis. Of these, 190 provided responses to the survey question regarding falls and are included in this analysis. Patients’ median age was 77 years; 50% were male.

Over one-quarter (25.2%) of patients reported a fall within the prior 12 months. In terms of comorbidities, among patients who reported 2 or more weeks of depression in the past year, 41.4% of patients reported a fall, compared with only 20.1% of those who did not report depression (P = .004). Patients who reported a fall were also more likely to report a history of congestive heart failure (22.7% fallers vs 7.9% nonfallers; P = .012). Fallers were more likely to report limitations in moderate activities (81.2% vs 62.1%; P = .015) and in climbing several flights of stairs (89.1% vs 64.9%; P = .001). Compared with nonfallers, fallers reported more days in the past 30 days when their physical health was not good (15.8 vs 10.0 days; P = .024), more days in the past 30 days when their mental health was not good (10.7 days vs 4.1 days; P = .002), and more days in the past 30 days when their health interfered with their daily activities (14.3 vs 7.0 days; P = .001). The median overall survival among fallers was 25.0 months versus 52.0 months among nonfallers.

The researchers concluded that falls are relatively common in older adults with newly diagnosed MM, and are associated with more limited activity, depression, and congestive heart failure. Additional studies are needed to elucidate factors that predict falls in order to proactively develop target interventions aimed at preventing falls, especially among high-risk patients with MM.

Related Items
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, AONN+ News
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Combining Immunotherapy and Radiotherapy Shows Good Synergy
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Immunotherapy, Conference Correspondent
Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News
Humanizing Cancer Care: The Patient Perspective
Gail Thompson
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ACCC
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Last modified: December 5, 2017